The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls
Abstract
INTRODUCTION: Adenoviruses (Ads) have attracted researchers from across the disciplines for several reasons. Their ability to recombine with and express the heterologous genes encouraged their development as gene/vaccine delivery vectors. Preclinical and clinical trials using these vectors have shown significant promise for their future development while highlighting certain limitations. AREAS COVERED: Ad vector development, clinical application of these vectors in gene therapy and vaccine development, and promises that these vectors offered for future development are discussed. Also, various factors affecting their in vivo efficacy as well as the strategies being pursued to overcome these obstacles are described. EXPERT OPINION: Decades of efforts have resulted in understanding various aspects of human Ad 5 biology as well as the in vivo behavior of vectors derived from this serotype. While this vector has shown great potential, some of the limitations highlighted in recent studies have reinforced the quest for an ideal vector derived from novel Ads. Combinatorial approaches to address the various limitations of the existing vectors must be pursued to develop novel vectors with enhanced clinical potential.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Adenoviruses (Ad) are non-enveloped, double-stranded DNA viruses with a packaging ability of 30 to 40 kb DNA [54].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [54]
Citations
Cites
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
Raper, S. E., Chirmule, N. B., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,531
Adenoviruses: update on structure and function
Russell, W. C. (2008) · Journal of General Virology · doi:10.1099/vir.0.003087-0 · Cited by 462
Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man
Barnes, E. J., Folgori, A., Capone, S., Swadling, L., Aston, S., Kurioka, A., Meyer, J., Huddart, R., Smith, K., Townsend, R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003155 · Cited by 404
Barouch, D. H., Kik, S. V., Weverling, G. J., Dilan, R., King, S. L., Maxfield, L. F., Clark, S., Ng’ang’a, D., Brandariz, K., Abbink, P., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.025 · Cited by 305
Virus-mediated gene delivery for human gene therapy
Giacca, M., & Zacchigna, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.008 · Cited by 302
Parker, A. L., Waddington, S. N., Nicol, C. G., Shayakhmetov, D. M., Buckley, S. M. K., Denby, L., Kemball‐Cook, G., Ni, S., Lieber, A., McVey, J. H., et al. (2006) · Blood · doi:10.1182/blood-2006-04-008532 · Cited by 297
Mast, T. C., Kierstead, L. S., Gupta, S. B., Nikas, A. A., Kallas, E. G., Novitsky, V., Mbewe, B., Pitisuttithum, P., Schechter, M., Vardas, E., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.145 · Cited by 283
Zhang, Y., & Bergelson, J. M. (2005) · Journal of Virology · doi:10.1128/jvi.79.19.12125-12131.2005 · Cited by 262
Vacchelli, E., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 260
Research works printed but not linked: 2
- Hemminki A, 2014, Scientifica (Cairo), 2014, 862925
- Harris JD, 2009, In Vivo, 23, 885
Cited by
Sorted by citations
Items 101–108 of 108
Potential Gene Therapy Options for Early OA
Madry, H., Cai, X., Oláh, T., Venkatesan, J. K., & Cucchiarini, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-79485-9_24
Recombinant Vaccines: The Revolution Ahead
Nayak, A. (2022) · Springer eBooks · doi:10.1007/978-981-19-3979-2_8
Clinical trials on oncolytic viruses
Головинов, И. В., Гончарова, А. С., Shulga, A. A., Николаевич, В. С., & Dimitriadi, S. N. (2025) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2024-4-158-168
Anchim, A. (2016) · theses.fr (ABES) · doi:10.70675/d10fb830z5afez4e17zb40fz3b23249344dc
Siniavin, A. E., Gushchin, V. A., Kuznetsova, N. A., Russu, L. I., Marchuk, E. V., Kleymenov, D. A., Nikiforova, M. A., Zubkova, O. V., Popova, O. D., Викторовна, В. И., et al. (2026) · Problems of Virology · doi:10.36233/0507-4088-353
Qiu, C., Zhou, Z., Yang, M., Wang, H., Li, X., Feng, Z., & Zhou, Y. (2026) · Pathogens · doi:10.3390/pathogens15060602
Zeng, X., Wang, Z., Cui, J., Wei, Y., Zhao, Q., Gu, B., & Gu, B. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108450
Metadata
- Authors
- Appaiahgari, M. B., & Vrati, S.
- Affiliations
- Translational Health Science and Technology Institute (IN)
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2014-12-22
- Volume
- 15
- Issue
- 3
- Pages
- 337-351
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2086054347
- Cited by
- 110
- References
- 97
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 7 · 2022: 6 · 2021: 11 · 2020: 11 · 2019: 13 · 2018: 14 · 2017: 12 · 2016: 16 · 2015: 7
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Biological Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adenovirus, gene delivery vectors, vaccine vectors, gene therapy, adenovirus type 5, heterologous expression
- MeSH terms
- Adenoviridae, Animals, Genetic Vectors, Humans, Viral Vaccines, Genetic Therapy, Drug Delivery Systems, Gene Transfer Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
